European buy-rated quality stocks with under 50% beta, cheap on P/E relatives and low crowding - UBS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 10 2024
0mins
Source: SeekingAlpha
- UBS Analysts Recommendations: UBS analysts have identified 15 European stocks that are buy-rated, high quality, cheap, and not crowded in terms of beta.
- Investment Strategy Note: Strategist Andrew Garthwaite advised investors to focus on quality defensives and highlighted these 15 European equities as meeting the criteria.
- Stock Criteria: The recommended stocks are high quality (top 40%), have a beta below 50%, are cheap based on P/E ratios (bottom 60%), and have a low crowding score (below 0.6).
- List of Recommended Stocks: The 15 European stocks include companies like Nestle S.A., Heineken N.V., Sanofi, and Swisscom AG among others.
- Market Comparison: The article also mentions reasons to prefer the European market over the U.S. and highlights top names with relatively expensive earnings volume for the season according to Barclays.
Analyst Views on SNY
Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 78.52 USD with a low forecast of 57.00 USD and a high forecast of 116.57 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 46.500
Low
57.00
Averages
78.52
High
116.57
Current: 46.500
Low
57.00
Averages
78.52
High
116.57
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
